SARS-CoV-2 Protein Linked to Severe Inflammation
Researchers discovered the nucleocapsid protein of SARS-CoV-2 triggers hyperinflammation in immune cells, potentially leading to vascular leakage in the heart and brain.
Researchers discovered the nucleocapsid protein of SARS-CoV-2 triggers hyperinflammation in immune cells, potentially leading to vascular leakage in the heart and brain.
Researchers have identified an immune cell population in human lung tissue that defends against viral, bacterial, and fungal infections.
A study shows that a loss of immunity caused flu and RSV peaks to occur earlier in the season before returning to pre-pandemic patterns.
Infants exposed to viruses by older siblings face a higher risk of hospitalization and long-term socioeconomic challenges, according to new research.
Enanta Pharma advanced zelicapavir into a registrational Phase 2b/3 clinical trial for adults at high risk of severe RSV outcomes.
Olorofim may provide a treatment option for patients with disseminated Valley Fever who have failed standard therapies.